drug
gemcitabine
Phase 1updated 5mo agoby Continuity Biosciences LLC
Phase 1community read0 votes
🐶 often sniffed alongside
top 8- tagApproval6 co-mentions · 3 sources
- drugGEMCITABINE HYDROCHLORIDE3 co-mentions · 3 sources
- tagOncology3 co-mentions · 1 sources
- drugpaclitaxel1 co-mentions · 1 sources
- drugSOR-0071 co-mentions · 1 sources
- drugpaclitaxel albumin bound1 co-mentions · 1 sources
- drugAG [gemcitabine + nab-paclitaxel]1 co-mentions · 1 sources
- companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying gemcitabine
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase3A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase3Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- phase2AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase2A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- phase2Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
News(8)
- Novocure hit by cyberattack exposing patient dataNovocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that unauthorized access to some of its information systems exposed patient and emp…fiercebiotech · 1mo ago
- Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ RhapsidoProcessa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.fiercebiotech · 2mo ago
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”biopharma_dive · 4mo ago
- Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBCA biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.onclive · 4mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 4mo ago
- Dr Pant on the Mechanism of Action of Daraxonrasib in PDACShubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.onclive · 5mo ago
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that